Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Pediatric Neurology

Multidisciplinary Care and Symptom Management

At a Glance

FAHN currently has no treatment that stops or reverses the disease, but coordinated supportive care can improve a child’s comfort, movement, communication, nutrition, and safety through individualized therapy, feeding support, medication, and monitoring.

Managing Fatty Acid Hydroxylase-associated Neurodegeneration (FAHN) focuses on supporting your child’s comfort, mobility, and overall quality of life. While there is currently no disease-modifying cure that can stop or reverse the condition, there are many supportive treatments available to manage symptoms and prevent complications [1][2].

Managing Movement and Muscle Tone

The most common challenges in FAHN are spasticity (muscle stiffness) and dystonia (involuntary twisting or posturing) [1][3].

  • Physical and Occupational Therapy: These are the foundation of care. An individualized, therapist-directed plan of stretching and range-of-motion exercises helps prevent contractures (permanent muscle tightening) [4][5]. Therapists can also recommend orthoses (braces), standing frames, and mobility aids. Do not independently force range of motion without guidance.
  • Oral Medications: Doctors may prescribe medications like baclofen to help relax muscles [5]. While helpful, baclofen can cause side effects like sleepiness, weakness, low muscle tone (hypotonia), and sometimes respiratory problems.
  • Botulinum Toxin Injections: For stiffness in specific muscle groups (like the calves), “Botox” injections can provide temporary relief [6][7]. However, these must be used cautiously under specialist supervision, as they can cause excessive weakness and carry specific risks if the child already has swallowing difficulties (dysphagia).
  • Advanced Interventions: If oral medications are not enough, a doctor might discuss an intrathecal baclofen pump, which delivers medicine directly to the spinal fluid [5]. This requires careful discussion of pump complications and the emergency risk of abrupt drug withdrawal if the pump fails. In some cases of severe dystonia, Deep Brain Stimulation (DBS) is considered, but this is an uncommon, highly specialized option with limited evidence in FAHN-specific dystonia [8][9].

Nutrition, Speech, and Swallowing

As FAHN progresses, the muscles used for speaking and swallowing can become weaker [1].

  • Communication Supports: A speech therapist can help with dysarthria (slurred speech). Many families use Augmentative and Alternative Communication (AAC) tools—ranging from simple picture boards to high-tech eye-tracking devices—to help their child express their needs [10][11].
  • Safe Swallowing: Aspiration (food or liquid entering the lungs) can be silent and occur even without coughing [12][13]. A speech-language pathologist or feeding team may recommend a swallowing study based on prolonged meals, fatigue, or recurrent chest symptoms. Do not thicken liquids or alter textures without individualized professional guidance.
  • Feeding Tubes: If oral feeding becomes unsafe, exhausting, or insufficient for growth, a gastrostomy tube (G-tube) may be considered [14]. A G-tube can supplement or replace oral intake. It is important to know that a G-tube does not entirely eliminate the risk of aspiration (from saliva or reflux) and is a shared decision based on growth, comfort, enjoyment of eating, and respiratory risks.

Bone Health and Seizures

Children with FAHN, especially those with reduced mobility, are at a higher risk for low bone density and fractures [15].

  • Bone Monitoring: Depending on your child’s mobility, fracture history, and medications, doctors may recommend a risk-based assessment of bone health. This can include checking serum calcium and Vitamin D levels, or performing DXA scans to monitor bone strength [16][17]. Supplements and weight-bearing activities (like standing frames) should be individualized for safety [18].
  • Seizure Management: If your child develops seizures, they will typically be managed by a pediatric neurologist using standard antiseizure medications and a personalized rescue plan [3][4].

The Future of Research

While current care is supportive, researchers are working to understand the biology of FAHN more deeply. Laboratory models are being used to study how the FA2H gene affects brain cells and to identify potential targets for future therapies [19][20]. Some research has explored dietary or lipid-based interventions in animal models, but these are not established treatments for humans and carry risks if tried outside of formal research studies [21][22]. Always check with your medical team or official clinical trial registries for the most current information.

Common questions in this guide

What care helps control movement problems in a child with FAHN?
Physical and occupational therapy are the foundation of care, using guided stretching, range-of-motion exercises, orthoses, standing frames, and mobility aids. Specialists may also consider baclofen or, in selected cases, botulinum toxin, an intrathecal baclofen pump, or deep brain stimulation. These options require individualized monitoring for side effects and complications.
How can we tell whether a child with FAHN has swallowing problems?
Aspiration can be silent, so the absence of coughing does not rule it out. Prolonged meals, fatigue while eating, or repeated chest symptoms may prompt evaluation by a speech-language pathologist or feeding team and possibly a swallowing study. Do not thicken liquids or change food textures without individualized professional guidance.
Does a G-tube prevent aspiration in FAHN?
No. A gastrostomy tube can supplement or replace oral feeding when eating is unsafe, exhausting, or not enough for growth, but it does not eliminate aspiration from saliva or reflux. The decision should consider growth, comfort, enjoyment of eating, and respiratory risks with the child’s care team.
What communication supports can help a child with FAHN?
Speech therapy can address dysarthria and help the child communicate more effectively. Augmentative and alternative communication tools may include picture boards, communication devices, or eye-tracking technology, depending on the child’s abilities and needs.
How are bone problems and seizures managed in FAHN?
Reduced mobility can increase the risk of low bone density and fractures, so clinicians may use risk-based calcium and vitamin D testing, DXA scans, and individualized weight-bearing activities. If seizures occur, a pediatric neurologist typically selects antiseizure medicine and creates a personalized rescue plan.
Are dietary or lipid treatments proven for FAHN?
Dietary and lipid-based approaches have been studied in laboratory or animal models, but they are not established treatments for people with FAHN. Families should not try these approaches without medical supervision and should ask the care team or an official clinical trial registry about current research.

Get notified when new evidence is published on Fatty acid hydroxylase-associated neurodegeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    FAHN/SPG35: a narrow phenotypic spectrum across disease classifications.

    Rattay TW, Lindig T, Baets J, et al.

    Brain : a journal of neurology 2019; (142(6)):1561-1572 doi:10.1093/brain/awz102.

    PMID: 31135052
  2. 2

    Hereditary spastic paraplegia: a practical approach.

    Bradley M, Kalfat A, Walsh RA, et al.

    Practical neurology 2026; doi:10.1136/pn-2026-005344.

    PMID: 42816178
  3. 3

    Clinical and neuroimaging features of autosomal recessive spastic paraplegia 35 (SPG35): case reports, new mutations, and brief literature review.

    Mari F, Berti B, Romano A, et al.

    Neurogenetics 2018; (19(2)):123-130 doi:10.1007/s10048-018-0538-8.

    PMID: 29423566
  4. 4

    A Rare Case of Fatty Acid Hydroxylase-Associated Neurodegeneration in a Pakistani Boy With a Homozygous FA2H Variant.

    Siddiqui AN, Siddiqui YN, Abbasi NUH, et al.

    Clinical case reports 2026; (14(10)):e73559 doi:10.1002/ccr3.73559.

    PMID: 42812484
  5. 5

    Rehabilitation management of children with hereditary spastic paraplegia: a retrospective cohort study.

    Paget SP, McIntyre S, Lewis J, et al.

    Developmental neurorehabilitation 2026; 1-8 doi:10.1080/17518423.2026.2738682.

    PMID: 42831377
  6. 6

    Botulinum Toxin-A Injection in the Treatment of Spasticity in a Infantile-Onset Neurodegeneration With Brain Iron Accumulation: A Case Report.

    Do HK, Jo GY, Kwon JK, Kim WJ

    Annals of rehabilitation medicine 2018; (42(2)):363-367 doi:10.5535/arm.2018.42.2.363.

    PMID: 29765892
  7. 7

    Treatment of Pantothenate-Kinase Neurodegeneration With Baclofen, Botulinum Toxin, and Deferiprone: A Case Report.

    Hameed M, Siddiqui F, Khan MK, et al.

    Brain & NeuroRehabilitation 2023; (16(3)):e25 doi:10.12786/bn.2023.16.e25.

    PMID: 38047104
  8. 8

    Deep Brain Stimulation (DBS) with Subthalamic Nucleus (STN) as Target for Pediatric Patients with PKAN.

    Li H, Li D, Yang W, et al.

    World neurosurgery 2022; (163()):e317-e322 doi:10.1016/j.wneu.2022.03.130.

    PMID: 35367641
  9. 9

    Deep brain stimulation for the treatment of paediatric dystonia due to neuroanatomical abnormalities: a systematic review of efficacy and future perspectives.

    Soliman Y, Figliomeni A, Lee H, et al.

    BMJ neurology open 2026; (8(1)):e001543 doi:10.1136/bmjno-2025-001543.

    PMID: 42158588
  10. 10

    Prescribing Assistive Technology: Focus on Children With Complex Communication Needs: Clinical Report.

    Desch LW, Hobart-Porter LJ, Houtrow A,

    Pediatrics 2025; (156(1)) doi:10.1542/peds.2025-072216.

    PMID: 40518139
  11. 11

    A Systematic Review of Augmentative and Alternative Communication Interventions for Children Aged From 0 to 6 Years.

    Leonet O, Orcasitas-Vicandi M, Langarika-Rocafort A, et al.

    Language, speech, and hearing services in schools 2022; (53(3)):894-920 doi:10.1044/2022_LSHSS-21-00191.

    PMID: 35759607
  12. 12

    Comprehensive assessment and treatment strategies for dysphagia in the elderly population: Current status and prospects.

    Hu X, Ma YN, Karako K, et al.

    Bioscience trends 2024; (18(2)):116-126 doi:10.5582/bst.2024.01100.

    PMID: 38658363
  13. 13

    Hereditary spastic paraplegia type 35 in a family from Mali.

    Landouré G, Dembélé K, Cissé L, et al.

    American journal of medical genetics. Part A 2019; (179(7)):1122-1125 doi:10.1002/ajmg.a.61179.

    PMID: 31087769
  14. 14

    Percutaneous endoscopic gastrostomy and jejunostomy: Indications and techniques.

    Fugazza A, Capogreco A, Cappello A, et al.

    World journal of gastrointestinal endoscopy 2022; (14(5)):250-266 doi:10.4253/wjge.v14.i5.250.

    PMID: 35719902
  15. 15

    Fractures in Children With Cerebral Palsy: A Systematic Review.

    Bentley LA, Taylor MJ, Brookes DSK, et al.

    Pediatrics 2026; (157(1)) doi:10.1542/peds.2025-072946.

    PMID: 41344381
  16. 16

    Vitamin D prophylaxis in persons with epilepsy?

    Sourbron J, Auvin S, Cabral-Lim L, et al.

    Epilepsia 2024; (65(9)):2567-2579 doi:10.1111/epi.18046.

    PMID: 39494692
  17. 17

    Bone Densitometry in Children and Adolescents.

    Bachrach LK, Gordon CM,

    Pediatrics 2016; (138(4)).

    PMID: 27669735
  18. 18

    Effect of standing frames used in real life on bone remodeling in non-walking children with cerebral palsy.

    Barbier V, Goëb V, Klein C, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2022; (33(9)):2019-2025 doi:10.1007/s00198-022-06436-5.

    PMID: 35614237
  19. 19

    A new model for fatty acid hydroxylase-associated neurodegeneration reveals mitochondrial and autophagy abnormalities.

    Mandik F, Kanana Y, Rody J, et al.

    Frontiers in cell and developmental biology 2022; (10()):1000553 doi:10.3389/fcell.2022.1000553.

    PMID: 36589738
  20. 20

    Disrupted Myelination in FAHN: Insights from a Patient-Specific hiPSC Neuron-Oligodendrocyte Model.

    Efendic F, Hermann A, Frech MJ

    Cells 2025; (14(16)) doi:10.3390/cells14161261.

    PMID: 40862740
  21. 21

    C. Elegans Fatty Acid Two-Hydroxylase Regulates Intestinal Homeostasis by Affecting Heptadecenoic Acid Production.

    Li Y, Wang C, Huang Y, et al.

    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2018; (49(3)):947-960 doi:10.1159/000493226.

    PMID: 30184537
  22. 22

    A Novel Homozygous Deletion Including Exon 1 of FA2H Gene Causes Spastic Paraplegia-35: Genetic and Lipidomics Analysis of the Patients.

    Mo L, Tie X, Che F, et al.

    Pediatric neurology 2024; (152()):200-208 doi:10.1016/j.pediatrneurol.2023.12.031.

    PMID: 38306901

This page explains supportive care options for a child with FAHN for educational purposes and does not replace medical advice. A child’s neurologist, rehabilitation team, and feeding specialists should tailor treatments, medications, and safety plans.

Guide contents Fatty acid hydroxylase-associated neurodegeneration
Research & Literature
03 The Biology and Diagnosis of FAHN 05 Building Your Care Team and Navigating Daily Life